Commonwealth legislation

National Health Act 1953 - Determination under subsection 85AB(1) (No. PB 66 of 2007)

RepealedCTH

This Act has been repealed and is no longer in force. It is retained for historical reference.

Jurisdiction

Commonwealth

Collection

legislative instrument

Plain English Summary

1/10 complexity

This determination adds two medicines—an amino‑acid synthetic infant formula supplemented with long‑chain polyunsaturated fatty acids and the biologic cetuximab—to F1 of the PBS, so pharmacists must dispense the exact brand the prescriber specifies.

That preserves brand‑specific efficacy and safety for a specialised nutritional product and a biological cancer therapy, but prevents switching to potentially cheaper generic or alternate brands.

JSON API Health / NDIS / medicines

Deep dive

Want the full deep dive?

Zoe can write the in-depth analysis on top of the summary above: how it works, who it affects and what each part actually does.

Current sections

Direct links to the current provisions in National Health Act 1953 - Determination under subsection 85AB(1) (No. PB 66 of 2007).

National Health Act 1953 - Determination under subsection 85AB(1) (No. PB 66 of 2007)

meta-content-style-type: text/css meta-content-type: application/xhtml+xml; charset=utf-8 meta-generator: Aspose.Words for .NET 20.2

?xml version="1.0" encoding="utf-8" standalone="no"?>

View image in the official source

COMMONWEALTH OF AUSTRALIA

Instrument number PB 66 of 2007

Determination under subsection 85AB(1) of the National Health Act 1953

I, STEPHEN DELLAR, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, make this instrument under subsection 85AB(1) of the National Health Act 1953.

Dated 14 August 2007

STEPHEN DELLAR

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

Determination – drugs on F1

1 Commencement

This instrument commences on 1 September 2007.

2 Drugs on F1

The listed drug “Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids” is on F1.

The listed drug “Cetuximab” is on F1.

Source text

Sourced from the Federal Register of Legislation (legislation.gov.au), CC BY 4.0.